Condition: Allergy · Peanut Allergy · Sponsor: DBV Technologies
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| AllerVie Clinical Research | Birmingham, Alabama, United States | — |
| University of Alabama at Birmingham Pediatric Primary Care Clinic | Birmingham, Alabama, United States | — |
| Modena Allergy & Asthma | Scottsdale, Arizona, United States | — |
| University of Arizona Asthma and Airway Disease Research Center | Tucson, Arizona, United States | — |
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | — |
| Modena Allergy & Asthma | La Jolla, California, United States | — |
| Modena Allergy and Asthma | Long Beach, California, United States | — |
| UCLA Health Westwood Pediatrics | Los Angeles, California, United States | — |
| Children's Hospital of Los Angeles | Los Angeles, California, United States | — |
| Allergy & Asthma Associates of Southern California | Mission Viejo, California, United States | — |
| Lucile Packard Children's Hospital Stanford | Palo Alto, California, United States | — |
| Allergy & Asthma Medical Group and Research Center | San Diego, California, United States | — |
+ 79 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.